IBOGF (Universal Ibogaine) Short-Term Debt: $0.59 Mil (As of Apr. 2025)


What is Universal Ibogaine Short-Term Debt?

Universal Ibogaine IBOGF -1.07% Short-Term Debt is $0.59 Mil as of Apr. 2025.

Universal Ibogaine's Short-Term Debt for the quarter that ended in Apr. 2025 was $0.59 Mil.

Universal Ibogaine's quarterly Short-Term Debt declined from Oct. 2024 ($0.08 Mil) to Jan. 2025 ($0.08 Mil) but then increased from Jan. 2025 ($0.08 Mil) to Apr. 2025 ($0.59 Mil).

Universal Ibogaine's annual Short-Term Debt increased from Jul. 2022 ($1.20 Mil) to Jul. 2023 ($1.36 Mil) but then declined from Jul. 2023 ($1.36 Mil) to Jul. 2024 ($0.08 Mil).

Universal Ibogaine Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Universal Ibogaine Short-Term Debt Related Terms

Universal Ibogaine Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Universal Ibogaine's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Universal Ibogaine Short-Term Debt Chart

Universal Ibogaine Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Jul22 Jul23 Jul24
Short-Term Debt
Get a 7-Day Free Trial 0.00 0.00 1.20 1.36 0.08

Universal Ibogaine Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.08 0.08 0.59
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $0.59 Mil mean?
Universal Ibogaine (IBOGF) has a Short-Term Debt of $0.59 Mil as of Apr. 2025.
Is Universal Ibogaine's Short-Term Debt too high?
Universal Ibogaine's current Short-Term Debt is $0.59 Mil.
How does Universal Ibogaine's Short-Term Debt compare to LABT and CALC?
Universal Ibogaine's Short-Term Debt of $0.59 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Universal Ibogaine's current Short-Term Debt is $0.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Universal Ibogaine stock overvalued right now?
Universal Ibogaine (IBOGF) has a current Short-Term Debt of $0.59 Mil. The current Short-Term Debt is $0.59 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Universal Ibogaine (IBOGF), the current Short-Term Debt is $0.59 Mil as of Apr. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Universal Ibogaine Business Description

Address C/o Cas Corporate Governance Services Inc, 815 - 8th Avenue South west, Suite 600, Calgary, AB, CAN, T2P 3P2
Universal Ibogaine Inc is in the initial stages of implementing and financing its business plan, which is to develop a network of addiction treatment clinics and to undertake a planned clinical trial for research in Canada into the use of ibogaine, a natural plant-based substance, for addiction treatment. Its mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.